Understanding patient needs myocardial metabolism: The diabetic heart

European Heart Journal, Supplement

Volumn 5, Issue B, 2003, Pages

  Ferrara, R ^a,b   Guardigli, G ^a,b   Ferrari, R ^a,b  

^a UNIVERSITY OF FERRARA   (Italy)

^b IRCCS   (Italy)

Author keywords

Cardiac metabolism; Coronary artery disease; Diabetes mellitus; Risk factors

Indexed keywords

ACETYL COENZYME A ACYLTRANSFERASE INHIBITOR; ANTIANGINA PECTORIS AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INSULIN; PRAVASTATIN; RANOLAZINE; SIMVASTATIN; STATINE DERIVATIVE; TRIMETAZIDINE; UNCLASSIFIED DRUG;

ANGINA PECTORIS; ARTICLE; CARBOHYDRATE METABOLISM; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; FATTY ACID OXIDATION; HEART FUNCTION; HEART MUSCLE METABOLISM; HUMAN; INSULIN RESISTANCE; INSULIN TREATMENT; ISCHEMIC HEART DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0037231892     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1520-765X(03)90036-8     Document Type: Article

References (19)

1. Kannel WB, McGee DL. Diabetes and glucose tolerance as a risk factors for cardiovascular disease: the Framingham study. Diabetes Care 1979; 2: 120-6.
2. Howard BV, Cowan LD, Go O, et al. adverse effects of diabetes on multiple cardiovascular disease risk factors in women: the Strong Heart Study. Diabetes Care 1998; 21: 1258-65.
3. Keaney JF Jr, Loscalzo J. Diabetes, oxidative stress, and platelet activation. Circulation 1999; 99: 189-91.
4. Williams SB, Goldfine AB, Timimi FK, et al. Acute hyperglycaemia attenuate endothelium-dependent in humans in vivo. Circulation 1998; 97: 1695-701.
5. Laakso M. Hyperglycaemia and cardiovascular disease in type 2 diabetes. Diabetes 1999; 48: 937-42.
6. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999;340:115-26.
7. Moreno PR, Murcia AM, Palacios IF, et al. Coronary composition and macrophages infiltration in atherectomy specimens from patients with diabetes mellitus. Circulation 2000; 102: 2180-4.
8. Kannel WB. Lipid, diabetes and coronary artery disease: insight from the Framingham study. Am Heart J 1985; 110: 1100-7.
9. Syvanne M, Taskinen M-R. Lipids and lipoproteins as coronary risk factors in non insulin-dependent diabetes mellitus. Lancet 1997; 350(suppl 1): 20-3.
10. Jokel R, Colwell JA. Arterial thrombosis in atherosclerosis in diabetes. Diabetes Rev 1997; 5: 316-30.
11. Van Wersch JWJ, Westerhuis LWJJM, Venekamp WJRR. Coagulation activation in diabetes mellitus. Haemostasis 1990; 20: 263-9.
12. Stanley WC, Lopaschuk GD, McCormack JG. Regulation of energy substrate metabolism in the diabetic heart. Cardiovasc Res 1997; 34: 25-33.
13. Shapiro LM, Howat AP, Calter MN. Left ventricular function in diabetes mellitus. Methodology and prevalence and spectrum of abnormalities. Br Heart J 1991; 45: 122-8.
14. Kannel WB, Hiortland M, Castellu WP. Role of diabetes in congestive heart failure: the Framingham Heart Study. Am J Cardiol 1974; 34: 29-34.
15. Marzilli M. Management of ischaemic heart disease in diabetic patients. Is there a role for cardiac metabolic agents? Curr Med Res Opin 2001; 17: 153-8.
16. Fath-Ordoubadi F, Beatt KJ. Glucose-insulin-potassium (GIK) therapy for treatment of acute myocardial infarction: an overview of randomized placebo controlled trials. Circulation 1997; 96: 1152-6.
17. Lopaschuk GD. Optimising cardiac energy metabolism: how can fatty acid and carbohydrate metabolism be manipulated? Coron Artery Dis 2001; 12(suppl 1): S8-11.
18. Kantor PF, Luvien A, KozaK R, Lopaschuk GD. The anginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 2-ketoacyl coenzyme A thiolase. Circ Res 2000; 86: 580-8.
19. Szwed H, Pachoki R, Domnzal-Bochenska M. The anti-ischaemic effect and tolerability of trimetazidine in coronary diabetic patients. A sub-study from Trimpol-1. Cardiovasc Drugs Ther 1999; 13: 215-20.